Last reviewed · How we verify
NCT04799379: EPHAS
Microporous Polysaccharide Hemospheres (MPH) Improving Outcome After Rectal Surgery
trial testing microporous polysaccharide hemospheres (MPH) agent in rectal surgery in Postoperative Sepsis in 130 participants. Completed in 30 June 2024.
31 December 2023
Quick facts
| Lead sponsor | Grupo Español de Rehabilitación Multimodal |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 130 |
| Start date | 1 April 2021 |
| Primary completion | 31 December 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 5 locations across Spain |
Drugs / interventions tested
- microporous polysaccharide hemospheres (MPH) agent in rectal surgery — full drug profile →
Conditions studied
- Postoperative Sepsis — all drugs for Postoperative Sepsis →
Sponsor
Grupo Español de Rehabilitación Multimodal — full company profile →
Who can join
18 and older, any sex, with Postoperative Sepsis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multi-center, prospective, cohort study, of patients scheduled for elective rectal surgery who received absorbable hemostatic powder to assess whether it can improve patient postoperative outcomes, reduce usage of drains and prove to be cost-effective. This cohort will be compared to a previously studied cohort using drains (Power and IMPRICA study) with comparable patient characteristics. The primary endpoint of the study is: postoperative pelvic sepsis within 60 postoperative days including anastomotic leakage, pelvic abscess and peritonitis. Secondary endpoints: postoperative morbidities, rate of reoperation and length of hospitalization.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Propensity score-matched analysis comparing drains and no-drains in rectal cancer surgery: the value of using a hemostatic agent instead - a prospective observational study.
Blanco FJ, Castillo J, Mariner S, Reig M, et al · · 2025 · cited 2× · PMID 40638367 · DOI 10.1097/js9.0000000000002965
Verify or expand the search:
- PubMed search for NCT04799379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Grupo Español de Rehabilitación Multimodal trials
Trials by the same sponsor.
- NCT06790238 — POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol After Gastric Surgery (POWER 4 + · active not recruiting
- NCT06369194 — POWER AUDIT, Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol · active not recruiting
- NCT04305314 — Long-term Enlarged Survival After an Enhanced Recovery Protocol (LESAS). · unknown
- NCT03864861 — Postoperative Outcomes Within an Enhanced Recovery After Bariatric Surgery Protocol · unknown
- NCT03865810 — Postoperative Outcomes Within an Enhanced Recovery After Surgery Protocol in Gastric Surgery for Cancer · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04799379 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Grupo Español de Rehabilitación Multimodal
- Last refreshed: 16 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04799379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing